Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study

摘要: Abstract Introduction Acquired haemophilia A (AHA) is an autoimmune disease that potentially leads to severe bleeding and has a high rate of mortality. This collaborative study aimed assess the efficacy co-administration FVIII low-dose rFVIIa in patients with AHA. Materials Methods retrospectively compared combined FVIII/low-dose therapy (initial dose range 25–55 μg/Kg) FVIII/PCC monotherapy. Adverse drug reactions recurrent episodes were also monitored. Crude comparisons exact conditional logistic regression performed compare outcomes between three treatment groups. Results First 56 consecutive from 5 centres analyzed, 37 (66.1%) determined be severe. Specifically, control was significantly higher alone or (58.3% vs. 41.7% 95.0%, respectively). Analyzing total 236 showed clear positive association early initiation haemostatic efficacy. No therapy-related adverse events which thrombosis predominated reported. Conclusions The combination offers ideal cover may promoted as feasible safe protocol for